1887
  1. الرئيسية
  2. A-Z Publications
  3. Global Cardiology Science and Practice
  4. المجلد 2015, العدد 1
  5. المقالة
Volume 2015, Issue 1
  • ISSN: 2305-7823
  • E-ISSN:

ملخص

The 21st century has seen a paradigm shift to inhaled therapy, for both systemic and local drug delivery, due to the lung's favourable properties of a large surface area and high permeability. Pulmonary drug delivery possesses many advantages, including non-invasive route of administration, low metabolic activity, control environment for systemic absorption and avoids first bypass metabolism. However, because the lung is one of the major ports of entry, it has multiple clearance mechanisms, which prevent foreign particles from entering the body. Although these clearance mechanisms maintain the sterility of the lung, clearance mechanisms can also act as barriers to the therapeutic effectiveness of inhaled drugs. This effectiveness is also influenced by the deposition site and delivered dose. Particulate-based drug delivery systems have emerged as an innovative and promising alternative to conventional inhaled drugs to circumvent pulmonary clearance mechanisms and provide enhanced therapeutic efficiency and controlled drug release. The principle of multiple pulmonary clearance mechanisms is reviewed, including mucociliary, alveolar macrophages, absorptive, and metabolic degradation. This review also discusses the current approaches and formulations developed to achieve optimal pulmonary drug delivery systems.

© 2015 El-Sherbiny, El-Baz, Yacoub, licensee Bloomsbury Qatar Foundation Journals.
Loading

جارٍ تحميل قياسات المقالة...

/content/journals/10.5339/gcsp.2015.2
٢٠١٥-٠٣-٠١
٢٠٢٤-٠٥-١٨
Loading full text...

Full text loading...

/deliver/fulltext/gcsp/2015/1/gcsp.2015.2.html?itemId=/content/journals/10.5339/gcsp.2015.2&mimeType=html&fmt=ahah

References

  1. Weers JG, Bell J, Chan H-K, Cipolla D, Dunbar C, Hickey AJ, Smith IJ. Pulmonary formulations: What remains to be done? Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2010; 23:S2:S-5–S-23.
     [Google الباحث العلمي]
  2. Courrier H, Butz N, Vandamme TF. Pulmonary drug delivery systems: Recent developments and prospects. Critical Reviews in Therapeutic Drug Carrier Systems. 2002; 19:4-5.
     [Google الباحث العلمي]
  3. Ungaro F, d'Angelo I, Miro A, La Rotonda MI, Quaglia F. Engineered PLGA nano-and micro-carriers for pulmonary delivery: Challenges and promises. Journal of Pharmacy and Pharmacology. 2012; 64:9:1217–1235.
     [Google الباحث العلمي]
  4. Marieb EN, Hoehn K. Human anatomy & physiology. Pearson Education 2007.
     [Google الباحث العلمي]
  5. Smola M, Vandamme T, Sokolowski A. Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases. International Journal of Nanomedicine. 2008; 3:1:1.
     [Google الباحث العلمي]
  6. Paranjpe M, Müller-Goymann CC. Nanoparticle-mediated pulmonary drug delivery: A review. International Journal of Molecular Sciences. 2014; 15:4:5852–5873.
     [Google الباحث العلمي]
  7. McCorry LK. Essentials of human physiology for pharmacy. CRC Press 2004.
     [Google الباحث العلمي]
  8. The Respiratory System-How the lung works. 2012 [2 July]:1-7; Available from: http://www.nhlbi.nih.gov/health/health-topics/topics/hlw/system.html .
  9. El-Sherbiny IM, Villanueva DG, Herrera D, Smyth HD. Overcoming lung clearance mechanisms for controlled release drug delivery. Controlled pulmonary drug delivery. Springer 2011;:101–126.
     [Google الباحث العلمي]
  10. Patton JS, Brain JD, Davies LA, Fiegel J, Gumbleton M, Kim K-J, Sakagami M, Vanbever R, Ehrhardt C. The particle has landed—characterizing the fate of inhaled pharmaceuticals. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2010; 23:S2:S-71–S-87.
     [Google الباحث العلمي]
  11. Hogg J. Response of the lung to inhaled particles. The Medical Journal of Australia. 1985; 142:13:675–678.
     [Google الباحث العلمي]
  12. Olsson B, Bondesson E, Borgström L, Edsbäcker S, Eirefelt S, Ekelund K, Ekelund K, Gustavsson L, Hegelund-Myrbäck T. Pulmonary drug metabolism, clearance, and absorption. Controlled pulmonary drug delivery. Springer 2011;:21–50.
     [Google الباحث العلمي]
  13. Oberdörster G. Lung clearance of inhaled insoluble and soluble particles. Journal of Aerosol Medicine. 1988; 1:4:289–330.
     [Google الباحث العلمي]
  14. Parkinson A. Biotransformation of xenobiotics. New York: McGraw-Hill 2001.
     [Google الباحث العلمي]
  15. Wiedmann T, Bhatia R, Wattenberg L. Drug solubilization in lung surfactant. Journal of Controlled Release. 2000; 65:1:43–47.
     [Google الباحث العلمي]
  16. Patton JS. Mechanisms of macromolecule absorption by the lungs. Advanced Drug Delivery Reviews. 1996; 19:1:3–36.
     [Google الباحث العلمي]
  17. Patton JS, Byron PR. Inhaling medicines: Delivering drugs to the body through the lungs. Nature Reviews Drug Discovery. 2007; 6:1:67–74.
     [Google الباحث العلمي]
  18. Liao X, Wiedmann TS. Solubilization of cationic drugs in lung surfactant. Pharmaceutical Research. 2003; 20:11:1858–1863.
     [Google الباحث العلمي]
  19. Mansour HM, Rhee Y-S, Wu X. Nanomedicine in pulmonary delivery. International Journal of Nanomedicine. 2009; 4::299.
     [Google الباحث العلمي]
  20. Beck-Broichsitter M, Gauss J, Packhaeuser CB, Lahnstein K, Schmehl T, Seeger W, Kissel T, Gessler T. Pulmonary drug delivery with aerosolizable nanoparticles in an ex vivo lung model. International Journal of Pharmaceutics. 2009; 367:1:169–178.
     [Google الباحث العلمي]
  21. Labiris N, Dolovich M. Pulmonary drug delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medications. British Journal of Clinical Pharmacology. 2003; 56:6:588–599.
     [Google الباحث العلمي]
  22. Davies C, Muir D. Deposition of inhaled particles in human lungs. Nature 1966; 211::90–91.
     [Google الباحث العلمي]
  23. Jain KK. Drug delivery systems-an overview. Drug delivery systems. Springer 2008;:1–50.
     [Google الباحث العلمي]
  24. Thulasiramaraju TV, Tejeswar Kumar B, Nikilesh Babu M. Pulmonary drug delivery systems-an overview. Asian Journal of Research in Pharmaceutical Sciences and Biotechnology. 2013;:16–34.
     [Google الباحث العلمي]
  25. Yang W, Peters JI, Williams III RO. Inhaled nanoparticles—a current review. International Journal of Pharmaceutics. 2008; 356:1:239–247.
     [Google الباحث العلمي]
  26. Boucher R. Regulation of airway surface liquid volume by human airway epithelia. Pfluegers Archiv. 2003; 445:4:495–498.
     [Google الباحث العلمي]
  27. Champion JA, Walker A, Mitragotri S. Role of particle size in phagocytosis of polymeric microspheres. Pharmaceutical Research. 2008; 25:8:1815–1821.
     [Google الباحث العلمي]
  28. Usmani OS, Biddiscombe MF, Underwood SR, Barnes PJ. Characterization of the generation of radiolabeled monodisperse albuterol particles using the spinning-top aerosol generator. Journal of Nuclear Medicine. 2004; 45:1:69–73.
     [Google الباحث العلمي]
  29. Edwards DA, Ben-Jebria A, Langer R. Recent advances in pulmonary drug delivery using large, porous inhaled particles. Journal of Applied Physiology. 1998; 85:2:379–385.
     [Google الباحث العلمي]
  30. Ehrhardt C, Fiegel J, Fuchs S, Abu-Dahab R, Schaefer U, Hanes J, Lehr CM. Drug absorption by the respiratory mucosa: Cell culture models and particulate drug carriers. Journal of Aerosol Medicine. 2002; 15:2:131–139.
     [Google الباحث العلمي]
  31. Tsapis N, Bennett D, Jackson B, Weitz DA, Edwards D. Trojan particles: Large porous carriers of nanoparticles for drug delivery. Proceedings of the National Academy of Sciences. 2002; 99:19:12001–12005.
     [Google الباحث العلمي]
  32. El-Sherbiny IM, McGill S, Smyth HD. Swellable microparticles as carriers for sustained pulmonary drug delivery. Journal of Pharmaceutical Sciences. 2010; 99:5:2343–2356.
     [Google الباحث العلمي]
  33. El-Sherbiny IM, Smyth HD. Biodegradable nano-micro carrier systems for sustained pulmonary drug delivery:(I) Self-assembled nanoparticles encapsulated in respirable/swellable semi-IPN microspheres. International Journal of Pharmaceutics. 2010; 395:1:132–141.
     [Google الباحث العلمي]
  34. Champion JA, Mitragotri S. Role of target geometry in phagocytosis. Proceedings of the National Academy of Sciences of the United States of America. 2006; 103:13:4930–4934.
     [Google الباحث العلمي]
  35. Champion JA, Mitragotri S. Shape induced inhibition of phagocytosis of polymer particles. Pharmaceutical Research. 2009; 26:1:244–249.
     [Google الباحث العلمي]
  36. Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nature Reviews Drug Discovery. 2003; 2:3:214–221.
     [Google الباحث العلمي]
  37. Suzuki Y, Yamaguchi T. Effects of hyaluronic acid on macrophage phagocytosis and active oxygen release. Agents and Actions. 1993; 38:1:32–37.
     [Google الباحث العلمي]
  38. Surendrakumar K, Martyn G, Hodgers E, Jansen M, Blair J. Sustained release of insulin from sodium hyaluronate based dry powder formulations after pulmonary delivery to beagle dogs. Journal of Controlled Release. 2003; 91:3:385–394.
     [Google الباحث العلمي]
  39. Evora C, Soriano I, Rogers RA, Shakesheff KM, Hanes J, Langer R. Relating the phagocytosis of microparticles by alveolar macrophages to surface chemistry: The effect of 1, 2-dipalmitoylphosphatidylcholine. Journal of Controlled Release. 1998; 51:2:143–152.
     [Google الباحث العلمي]
  40. Hickey AJ. Pharmaceutical inhalation aerosol technology. CRC Press 2003.
     [Google الباحث العلمي]
  41. Niven RW, Whitcomb KL, Shaner L, Ip AY, Kinstler OB. The pulmonary absorption of aerosolized and intratracheally instilled rhG-CSF and monoPEGylated rhG-CSF. Pharmaceutical Research. 1995; 12:9:1343–1349.
     [Google الباحث العلمي]
  42. Meenach SA, Vogt FG, Anderson KW, Hilt JZ, McGarry RC, Mansour HM. Design, physicochemical characterization, and optimization of organic solution advanced spray-dried inhalable dipalmitoylphosphatidylcholine (DPPC) and dipalmitoylphosphatidylethanolamine poly (ethylene glycol)(DPPE-PEG) microparticles and nanoparticles for targeted respiratory nanomedicine delivery as dry powder inhalation aerosols. International Journal of Nanomedicine. 2013; 8::275.
     [Google الباحث العلمي]
  43. Jaafar-Maalej C, Elaissari A, Fessi H. Lipid-based carriers: Manufacturing and applications for pulmonary route. Expert Opinion on Drug Delivery. 2012; 9:9:1111–1127.
     [Google الباحث العلمي]
  44. Lasic DD. Liposomes in gene delivery. CRC press 1997.
     [Google الباحث العلمي]
  45. Bai S, Gupta V, Ahsan F. Cationic liposomes as carriers for aerosolized formulations of an anionic drug: Safety and efficacy study. European Journal of Pharmaceutical Sciences. 2009; 38:2:165–171.
     [Google الباحث العلمي]
  46. Kaur G, Narang R, Rath G, Goyal AK. Advances in pulmonary delivery of nanoparticles. Artificial Cells, Blood Substitutes and Biotechnology. 2012; 40:1-2:75–96.
     [Google الباحث العلمي]
  47. Schreier H, Gonzalez-Rothi RJ, Stecenko AA. Pulmonary delivery of liposomes. Journal of Controlled Release. 1993; 24:1:209–223.
     [Google الباحث العلمي]
  48. Saari SM, Vidgren MT, Koskinen MO, Turjanmaa ViM, Waldrep JC, Nieminen MM. Regional lung deposition and clearance of 99mTc-labeled beclomethasone-DLPC liposomes in mild and severe asthma. CHEST Journal. 1998; 113:6:1573–1579.
     [Google الباحث العلمي]
  49. Arppe J, Vidgren M, Waldrep J. Pulmonary pharmacokinetics of cyclosporin A liposomes. International Journal of Pharmaceutics. 1998; 161:2:205–214.
     [Google الباحث العلمي]
  50. Poyner E, Alpar H, Almeida A, Gamble M, Brown M. A comparative study on the pulmonary delivery of tobramycin encapsulated into liposomes and PLA microspheres following intravenous and endotracheal delivery. Journal of Controlled Release. 1995; 35:1:41–48.
     [Google الباحث العلمي]
  51. Gibbons AM, McElvaney NG, Taggart CC, Cryan S-A. Delivery of rSLPI in a liposomal carrier for inhalation provides protection against cathepsin L degradation. Journal of Microencapsulation. 2009; 26:6:513–522.
     [Google الباحث العلمي]
  52. Shahiwala A, Misra A. Pulmonary absorption of liposomal levonorgestrel. AAPS PharmSciTech. 2004; 5:1:96–100.
     [Google الباحث العلمي]
  53. Nag OK, Awasthi V. Surface engineering of liposomes for stealth behavior. Pharmaceutics. 2013; 5:4:542–569.
     [Google الباحث العلمي]
  54. Beck-Broichsitter M, Ruppert C, Schmehl T, Guenther A, Betz T, Bakowsky U, Seeger W, Kissel T, Gessler T. Biophysical investigation of pulmonary surfactant surface properties upon contact with polymeric nanoparticles in vitro. Nanomedicine: Nanotechnology, Biology and Medicine. 2011; 7:3:341–350.
     [Google الباحث العلمي]
  55. Nassimi M, Schleh C, Lauenstein H, Hussein R, Hoymann H, Koch W, Pohlmann G, Krug N, Sewald K, Rittinghausen S, Braun A, Müller-Goymann C. A toxicological evaluation of inhaled solid lipid nanoparticles used as a potential drug delivery system for the lung. European Journal of Pharmaceutics and Biopharmaceutics. 2010; 75:2:107–116.
     [Google الباحث العلمي]
  56. Nassimi M, Schleh C, Lauenstein H-D, Hussein R, Lübbers K, Pohlmann G, Switalla S, Sewald K, Müller M, Krug N, Müller-Goymann CC, Braun A. Low cytotoxicity of solid lipid nanoparticles in in vitro and ex vivo lung models. Inhalation Toxicology. 2009; 21:S1:104–109.
     [Google الباحث العلمي]
  57. Liu J, Gong T, Fu H, Wang C, Wang X, Chen Q, Zhang Q, He Q, Zhang Z. Solid lipid nanoparticles for pulmonary delivery of insulin. International Journal of Pharmaceutics. 2008; 356:1:333–344.
     [Google الباحث العلمي]
  58. Yang W, Tam J, Miller DA, Zhou J, McConville JT, Johnston KP, Williams RO 3rd. High bioavailability from nebulized itraconazole nanoparticle dispersions with biocompatible stabilizers. International Journal of Pharmaceutics. 2008; 361:1:177–188.
     [Google الباحث العلمي]
  59. MuÈller RH, MaÈder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery–a review of the state of the art. European Journal of Pharmaceutics and Biopharmaceutics. 2000; 50:1:161–177.
     [Google الباحث العلمي]
  60. Li Y-Z, Sun X, Gong T, Liu J, Zuo J, Zhang Z-R. Inhalable microparticles as carriers for pulmonary delivery of thymopentin-loaded solid lipid nanoparticles. Pharmaceutical Research. 2010; 27:9:1977–1986.
     [Google الباحث العلمي]
  61. Weber S, Zimmer A, Pardeike J. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for pulmonary application: A review of the state of the art. European Journal of Pharmaceutics and Biopharmaceutics. 2014; 86:1:7–22.
     [Google الباحث العلمي]
  62. Illum L, Watts PJ. Polysaccharide microspheres for the pulmonary delivery of drugs. Google Patents 1997.
     [Google الباحث العلمي]
  63. Feng S-S, Chien S. Chemotherapeutic engineering: Application and further development of chemical engineering principles for chemotherapy of cancer and other diseases. Chemical Engineering Science. 2003; 58:18:4087–4114.
     [Google الباحث العلمي]
  64. Williams III RO, Barron MK, José Alonso M, Remuñán-López C. Investigation of a pMDI system containing chitosan microspheres and P134a. International Journal of Pharmaceutics. 1998; 174:1:209–222.
     [Google الباحث العلمي]
  65. Wang H, Xu Y, Zhou X. Docetaxel-loaded chitosan microspheres as a lung targeted drug delivery system: In vitro and in vivo evaluation. International Journal of Molecular Sciences. 2014; 15:3:3519–3532.
     [Google الباحث العلمي]
  66. Doan T, Olivier J. Preparation of rifampicin-loaded PLGA microspheres for lung delivery as aerosol by premix membrane homogenization. International Journal of Pharmaceutics. 2009; 382:1:61–66.
     [Google الباحث العلمي]
  67. Grenha A, Grainger CI, Dailey LA, Seijo B, Martin GP, Remuñán-López C, Forbes B. Chitosan nanoparticles are compatible with respiratory epithelial cells in vitro. European Journal of Pharmaceutical Sciences. 2007; 31:2:73–84.
     [Google الباحث العلمي]
  68. Kaye RS, Purewal TS, Alpar HO. Simultaneously manufactured nano-in-micro (SIMANIM) particles for dry-powder modified-release delivery of antibodies. Journal of Pharmaceutical Sciences. 2009; 98:11:4055–4068.
     [Google الباحث العلمي]
  69. Marsh D, Bartucci R, Sportelli L. Lipid membranes with grafted polymers: Physicochemical aspects. Biochimica et Biophysica Acta (BBA)-Biomembranes. 2003; 1615:1:33–59.
     [Google الباحث العلمي]
  70. Davidsen J, Vermehren C, Frokjaer S, Mouritsen OG, Jørgensen K. Drug delivery by phospholipase A2 degradable liposomes. International Journal of Pharmaceutics. 2001; 214:1:67–69.
     [Google الباحث العلمي]
  71. Lavasanifar A, Samuel J, Kwon GS. Poly (ethylene oxide)-block-poly (l-amino acid) micelles for drug delivery. Advanced Drug Delivery Reviews. 2002; 54:2:169–190.
     [Google الباحث العلمي]
  72. Gaber NN, Darwis Y, Peh K-K, Tan YT-F. Characterization of polymeric micelles for pulmonary delivery of beclomethasone dipropionate. Journal of Nanoscience and Nanotechnology. 2006; 6:9-10:3095–3101.
     [Google الباحث العلمي]
  73. Duchêne D, Ponchel G, Wouessidjewe D. Cyclodextrins in targeting: Application to nanoparticles. Advanced Drug Delivery Reviews. 1999; 36:1:29–40.
     [Google الباحث العلمي]
  74. Duchene D, Wouessidjewe D, Ponchel G. Cyclodextrins and carrier systems. Journal of Controlled Release. 1999; 62:1:263–268.
     [Google الباحث العلمي]
  75. Yang W, Chow KT, Lang B, Wiederhold NP, Johnston KP, Williams III RO. In vitro characterization and pharmacokinetics in mice following pulmonary delivery of itraconazole as cyclodextrin solubilized solution. European Journal of Pharmaceutical Sciences. 2010; 39:5:336–347.
     [Google الباحث العلمي]
  76. Tolman JA, Nelson NA, Son YJ, Bosselmann S, Wiederhold NP, Peters JI, McConville JT, Williams RO 3rd. Characterization and pharmacokinetic analysis of aerosolized aqueous voriconazole solution. European Journal of Pharmaceutics and Biopharmaceutics. 2009; 72:1:199–205.
     [Google الباحث العلمي]
  77. Ungaro F, d'Emmanuele di Villa Bianca R, Giovino C, Miro A, Sorrentino R, Quaglia F, La Rotonda MI. Insulin-loaded PLGA/cyclodextrin large porous particles with improved aerosolization properties: In vivo deposition and hypoglycaemic activity after delivery to rat lungs. Journal of Controlled Release. 2009; 135:1:25–34.
     [Google الباحث العلمي]
  78. Jalalipour M, Najafabadi AR, Gilani K, Esmaily H, Tajerzadeh H. Effect of dimethyl-β-cyclodextrin concentrations on the pulmonary delivery of recombinant human growth hormone dry powder in rats. Journal of Pharmaceutical Sciences. 2008; 97:12:5176–5185.
     [Google الباحث العلمي]
  79. Makino K. Pulmonary drug delivery system. [Available from: http://www.tus.ac.jp/rist/lab/introduction/2research-centers/906.html .
     [Google الباحث العلمي]
http://instance.metastore.ingenta.com/content/journals/10.5339/gcsp.2015.2
Loading
Inhaled nano- and microparticles for drug delivery
Global Cardiology Science and Practice 2015, 2 (٢٠١٥); https://doi.org/10.5339/gcsp.2015.2
/content/journals/10.5339/gcsp.2015.2
/content/journals/10.5339/gcsp.2015.2
Loading

جارٍ تحميل البيانات والوسائط...

  • نوع المستند: Review Article
الموضوعات الرئيسية bioavailability, liposomes, micelles, particulate-based drug delivery system, polymeric micro/nanoparticles, pulmonary clearance mechanisms, pulmonary delivery and solid lipid nanoparticles
هذه الخانة مطلوبة
يُرجى إدخال عنوان بريد إلكتروني صالح
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error